Like S100B, increased S100A4 levels is linked to poor survival in cancer patients.206–207 Therefore, developing S100-specific inhibitors is of great interest to counteract these disease states, and thus understanding how to interrupt these allosteric biomolecular interactions represents an opportunity to address such diseases therapeutically. The gene discussed is S100A4; the disease is cancer.